<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00923091</url>
  </required_header>
  <id_info>
    <org_study_id>CS8635-A-E302</org_study_id>
    <nct_id>NCT00923091</nct_id>
  </id_info>
  <brief_title>Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension</brief_title>
  <official_title>Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination in Subjects With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the change in blood pressure from the administration of
      Olmesartan/Amlodipine/Hydrochlorothiazide triple combinations compared to dual combinations
      with Olmesartan/Amlodipine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Seated Diastolic Blood Pressure (SeDBP).</measure>
    <time_frame>Baseline to week 10</time_frame>
    <description>Baseline blood pressure was defined as the average values obtained at the randomization visit and at the visit prior to randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Seated Systolic Blood Pressure (SeDBP).</measure>
    <time_frame>Baseline to week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reaching Blood Pressure Goal at Week 10</measure>
    <time_frame>baseline to week 10</time_frame>
    <description>Blood pressure treatment goal was defined as blood pressure &lt;140/90 mmHg or &lt;130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Seated Diastolic Blood Pressure From Week 18 to Week 22</measure>
    <time_frame>Week 18 to week 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Seated Systolic Blood Pressure From Week 18 to Week 22</measure>
    <time_frame>Week 18 to week 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reaching Blood Pressure Goal From Week 18 to Week 22</measure>
    <time_frame>Week 18 to week 22</time_frame>
    <description>Blood pressure treatment goal was defined as blood pressure &lt;140/90 mmHg or &lt;130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Seated Diastolic Blood Pressure From Week 22 to Week 26</measure>
    <time_frame>Week 22 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Seated Systolic Blood Pressure From Week 22 to Week 26</measure>
    <time_frame>Week 22 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reaching Blood Pressure Goal at Week 26</measure>
    <time_frame>Week 22 to week 26</time_frame>
    <description>Blood pressure treatment goal was defined as blood pressure &lt;140/90 mmHg or &lt;130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Seated Systolic Blood Pressure (SeDBP) During Open-Label Period VI (Titration Effect From OM/AML/HCTZ 40/5/25 to 40/10/25.</measure>
    <time_frame>Week 26 to week 54</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">2689</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>olmesartan/amlodipine/hydrochlorothiazide 20mg/5mg/12.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olmesartan medoxomil 20mg / amlodipine besylate 5 mg / hydrochlorothiazide 12.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/12.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/12.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>olmesartan/amlodipine 20mg/5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olmesartan medoxomil 20mg / amlodipine besylate 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olmesartan/amlodipine 40mg/5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>olmesartan/amlodipine 40mg/10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo</intervention_name>
    <description>One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.</description>
    <arm_group_label>olmesartan/amlodipine/hydrochlorothiazide 20mg/5mg/12.5mg</arm_group_label>
    <other_name>Azor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo</intervention_name>
    <description>One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.</description>
    <arm_group_label>olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/12.5mg</arm_group_label>
    <other_name>Azor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil + amlodipine + hydroclororthiazide</intervention_name>
    <description>One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.</description>
    <arm_group_label>olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/25mg</arm_group_label>
    <other_name>Azor</other_name>
    <other_name>Norvasc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil + amlodipine + hydroclororthiazide</intervention_name>
    <description>One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.</description>
    <arm_group_label>olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/12.5mg</arm_group_label>
    <other_name>Azor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil + amlodipine + hydroclororthiazide</intervention_name>
    <description>One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.</description>
    <arm_group_label>olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/25mg</arm_group_label>
    <other_name>Azor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil + amlodipine</intervention_name>
    <description>One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day</description>
    <arm_group_label>olmesartan/amlodipine 20mg/5mg</arm_group_label>
    <other_name>Azor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil + amlodipine</intervention_name>
    <description>One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.</description>
    <arm_group_label>olmesartan/amlodipine 40mg/5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil + amlodipine</intervention_name>
    <description>One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.</description>
    <arm_group_label>olmesartan/amlodipine 40mg/10mg</arm_group_label>
    <other_name>Azor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 18 years or older.

          -  Subjects with mean trough seated blood pressure (SeBP) ≥ 160/100 mmHg, (seated
             systolic blood pressure(SeSBP) ≥ 160 mmHg and seated diastolic blood pressure (SeDBP)
             ≥ 100 mmHg) at Screening if not currently on antihypertensive medication (newly
             diagnosed subjects or subjects who are not taking any antihypertensive medication for
             at least 3 weeks); Or Subjects with mean trough SeBP ≥ 160/100 mmHg, SeSBP ≥ 160 mmHg
             and SeDBP ≥ 100 mmHg) after washout of prior antihypertensive medication in subjects
             who discontinued their previous antihypertensive medication.

        The difference in mean SeSBP/SeDBP between the visit prior to randomisation and the
        randomisation visit must be ≤ 20/10 mmHg. Subjects not currently on antihypertensive (HTN)
        medication may meet this requirement at the screening visit (Visit 1) and the randomization
        visit (Visit 3). Subjects washing out of HTN medication must meet this requirement at least
        by Visit 2 (or Visit 2.1, if needed) and Visit 3. All subjects undergoing washout of their
        prior antihypertensive medication will have the opportunity to re-visit the study sites for
        additional visits during washout (Visits 2 and 2.1) to assess eligibility for
        randomisation.

          -  Subjects freely sign the informed consent form (ICF) after the nature of the study and
             the disclosure of his/her data has been explained.

          -  Female subjects of childbearing potential must be using adequate contraception (female
             of childbearing potential is defined as one who has not been postmenopausal for at
             least one year, or has not been surgically sterilised, or has not had a hysterectomy
             at least three months prior to the start of this study [Visit 1]). Adequate
             contraceptives include hormonal intra-uterine devices, hormonal contraceptives (oral,
             depot, patch or injectable), and double barrier methods such as condoms or diaphragms
             with spermicidal gel or foam.

        Exclusion Criteria:

          -  Female subjects of childbearing potential who are pregnant or lactating.

          -  Subjects with serious disorders which may limit the ability to evaluate the efficacy
             or safety of the investigational products, including cerebrovascular, cardiovascular,
             renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematologic
             or, neurologic, and psychiatric diseases. The same applies for immunocompromised
             and/or neutropenic subjects.

          -  Subjects having a history of the following within the last six months: myocardial
             infarction (MI), unstable angina pectoris, percutaneous coronary intervention, heart
             failure, hypertensive encephalopathy, cerebrovascular accident (stroke), or transient
             ischaemic attack.

          -  Subjects with clinically significant abnormal laboratory values at Screening,
             including subjects with one or more of the following:

               -  Aspartate aminotransferase (AST) &gt; 3 times upper limit of normal (ULN).

               -  Alanine aminotransferase (ALT) &gt; 3 times ULN.

               -  Gamma-glutamyl transferase (GGT) &gt; 3 times ULN.

               -  Potassium above ULN (unless high value is due to haemolytic blood sample).

          -  Subjects with secondary hypertension of any aetiology such as renal disease,
             phaeochromocytoma, or Cushing's syndrome.

          -  Subjects with contraindication to olmesartan, amlodipine, hydrochlorothiazide, or any
             of the tablet's excipients.

          -  Newly diagnosed subjects with a mean trough SeSBP &gt; 200 mmHg or mean trough SeDBP &gt;
             115 mmHg or any subjects with bradycardia (heart rate &lt; 50 beats/min at rest
             documented by mean radial pulse rate [PR] or electrocardiogram [ECG]) at Screening
             (Visit 1) or immediately before taking Period I study medication (Visit 3).

          -  Subjects already taking four or more antihypertensive medications.

          -  Subjects with a mean trough SeSBP &gt; 145 mmHg or mean trough SeDBP &gt; 95 mmHg while
             taking three antihypertensive medications.

          -  Subjects with a mean trough SeSBP &gt; 160 mmHg or mean trough SeDBP &gt; 100 mmHg while
             taking two antihypertensive medications.

          -  Subjects with a mean trough SeSBP &gt; 180 mmHg or mean trough SeDBP &gt; 110 mmHg while
             taking one antihypertensive medication.

          -  Subjects with electrocardiogram evidence of 2nd or 3rd degree atrio ventricular (AV)
             block, atrial fibrillation, or other cardiac arrhythmia (requiring treatment).

          -  Subjects with severe heart failure (New York Heart Association stage III-IV),
             clinically significant aortic or mitral valve stenosis, uncorrected coarctation of the
             aorta, obstruction of cardiac outflow (obstructive, hypertrophic cardiomyopathy) or
             symptomatic coronary disease.

          -  Subjects with clinical evidence of renal disease including reno-vascular occlusive
             disease, nephrectomy and/or renal transplant, bilateral renal artery stenosis,
             unilateral renal artery stenosis in a solitary kidney, or severe renal impairment as
             evidenced by CrCl of &lt; 30 mL/min calculated using the Cockcroft and Gault formula.

          -  Subjects with clinically relevant hepatic impairment.

          -  Subjects with biliary obstruction.

          -  Subjects with uncontrolled Type 1 or Type 2 diabetes defined as HbA1c &gt; 9.0%.
             Diabetics must have documentation of HbA1c within 6 months of the Screening Visit, or
             must have their HbA1c assessed prior to randomisation. Note: subjects with Type 1 or
             Type 2 diabetes controlled with insulin, diet or oral hypoglycaemic agents on a stable
             dose for at least 30 days may be included.

          -  Subjects with a history of a wasting disease (e.g. cancer), autoimmune diseases,
             connective tissue diseases, major allergies or angioneurotic oedema.

          -  Subjects who require or are taking any concomitant medication which may interfere with
             the objectives of the study.

          -  Subjects on beta blockers or calcium channel blockers (CCBs) for both hypertension and
             either ischemia, post-MI prophylaxis or tachyarrhythmias.

          -  Subjects with known malabsorption syndromes.

          -  Subjects with psychiatric or emotional problems, which would invalidate the giving of
             informed consent or limit the ability of the subject to comply with study
             requirements.

          -  Subjects with a history of alcohol and/or drug abuse.

          -  Subjects who have received any investigational agent within 30 days prior to
             Screening.

          -  Subjects who are unwilling or unable to provide informed consent or to participate
             satisfactorily for the entire study.

          -  Subjects with malignancy during the past 2 years excluding squamous cell or basal cell
             carcinoma of the skin.

          -  Subjects with signs or symptoms which could exacerbate the occurrence of hypotension
             such as volume and salt depletion.

          -  Subjects with any medical condition, which in the judgment of the Investigator would
             jeopardise the evaluation of efficacy or safety and/or constitute a significant safety
             risk to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buizingen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>De Pinte</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Drongen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gilly</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mouscron</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tremelo</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichelen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burgas</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veliko Tarnovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Benatky nad Jizerou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brodce</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Havirov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jicin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mlada Boleslav</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moravska Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prachatice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sokolov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frederiksberg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cloppenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delitzsch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northeim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simmern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wallerfing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hodmezovasarhely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaszbereny</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oroshaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szekesfehervar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veszprem</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stradella Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cesis</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jekabpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogre</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tukums</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varaklani</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ventspils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deurne</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lichtenvoorde</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lieshout</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debica</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jastrzebia Zdroj</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mielec</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Opole</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pitesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suceava</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banska Bysterica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratilslava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Povazska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rimavska Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ferrol</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petrer</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lutsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simferopol</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zhytomyr</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <results_first_submitted>January 30, 2012</results_first_submitted>
  <results_first_submitted_qc>March 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2012</results_first_posted>
  <last_update_submitted>April 6, 2012</last_update_submitted>
  <last_update_submitted_qc>April 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>triple combination</keyword>
  <keyword>parallel group</keyword>
  <keyword>dual combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conduct in Europe from 27 May 2009 to 12 January 2011</recruitment_details>
      <pre_assignment_details>Study has randomised, double-blind, placebo-controlled parallel-group portion (Periods I–II) followed by transition phase (Periods III–V) wherein combination titration steps were evaluated in subjects not achieving blood pressure goals. The transition required that all be entered into Period 3 on olm/aml/hctz 20/5/12.5 to ensure a common baseline.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5mg</title>
          <description>Once a day the following tablets were taken: 1 tablet of olmesartan 20 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet. In Periods I/II participants were randomized to this and the other 7 arms arms in a 1:1:1:1:1:1:1:1 fashion. In Period III, all participants were included in this group. Responders (a participant was considered a responder if their blood pressure was &lt;140/90 mm Hg; &lt;130/80 mm Hg if the participant had diabetes or chronic renal or cardiovascular disease) in Period III went directly to Period VI. In Period IV participants who did not meet the blood pressure goals in Period III were randomized in a 1:2 fashion to this group or the OLM/AML/HCTZ 40/5/12.5 group.</description>
        </group>
        <group group_id="P2">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg</title>
          <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet. In Periods I/II participants were randomized to this and the other 7 arms arms in a 1:1:1:1:1:1:1:1 fashion. In Period IV participants who did not meet the blood pressure goals (&lt;140/90 mm Hg; or &lt;130/80 for participants with diabetes or chronic renal or cardiovascular disease)in Period III were randomized in a 1:2 fashion to OLM/AML/HCTZ 20/5/12.5 or this group.</description>
        </group>
        <group group_id="P3">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg</title>
          <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + 2 tablets of hydroclororthiazide 12.5 mg. In Periods I/II participants were randomized to this and the other 7 arms arms in a 1:1:1:1:1:1:1:1 fashion.</description>
        </group>
        <group group_id="P4">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg</title>
          <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet. In Periods I/II participants were randomized to this and the other 7 arms arms in a 1:1:1:1:1:1:1:1 fashion.</description>
        </group>
        <group group_id="P5">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide(HCT) 40mg/10mg/25mg</title>
          <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + 2 tablets of hydroclororthiazide 12.5 mg. In Periods I/II participants were randomized to this and the other 7 arms arms in a 1:1:1:1:1:1:1:1 fashion.</description>
        </group>
        <group group_id="P6">
          <title>Olmesartan(OM)20mg/Amlodipine (AML)5mg</title>
          <description>Once a day the following tablets were taken: 1 tablet of olmesartan 20 mg/amlodipine 5 mg + two 12.5 mg hydrochlorothiazide placebo tablets. In Periods I/II participants were randomized to this and the other 7 arms arms in a 1:1:1:1:1:1:1:1 fashion.</description>
        </group>
        <group group_id="P7">
          <title>Olmesartan/Amlodipine 40mg/5mg</title>
          <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + two 12.5 mg hydrochlorothiazide placebo tablets. In Periods I/II participants were randomized to this and the other 7 arms arms in a 1:1:1:1:1:1:1:1 fashion.</description>
        </group>
        <group group_id="P8">
          <title>Olmesartan/Amlodipine 40mg/10mg</title>
          <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + two 12.5 mg hydrochlorothiazide placebo tablets. In Periods I/II participants were randomized to this and the other 7 arms arms in a 1:1:1:1:1:1:1:1 fashion.</description>
        </group>
        <group group_id="P9">
          <title>OM/AML/HCT 40/5/12.5mg Responder Continued on 40/5/12.5 mg</title>
          <description>In Period V responders continued on olmesartan/amlodipine/ hydrochlorothiazide 40mg/5mg/12.5 mg. A participant was considered a responder if their blood pressure was &lt;140/90 mm Hg; &lt;130/80 mm Hg if the participant had diabetes or chronic renal or cardiovascular disease.</description>
        </group>
        <group group_id="P10">
          <title>OM/AML/HCT 40/5/12.5mg Non Responder Randomized to 40/5/12.5mg</title>
          <description>In Period V OLM/AML/HCTZ 40/5/12.5 non-responders were randomized to olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/12.5 mg or to 40mg/5mg/25 mg. A participant was considered a responder if their blood pressure was &lt;140/90 mm Hg; &lt;130/80 mm Hg if the participant had diabetes or chronic renal or cardiovascular disease.</description>
        </group>
        <group group_id="P11">
          <title>OM/AML/HCT 40/5/12.5mg Non Responder Randomized to 40/5/25mg</title>
          <description>In Period V OLM/AML/HCTZ 40/5/12.5 non-responders were randomized to olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/12.5 mg or to 40mg/5mg/25 mg. A participant was considered a responder if their blood pressure was &lt;140/90 mm Hg; &lt;130/80 mm Hg if the participant had diabetes or chronic renal or cardiovascular disease.</description>
        </group>
        <group group_id="P12">
          <title>OM/AML/HCT 20/5/12.5mg NonResponder Up Titrated to 40/5/12.5mg</title>
          <description>In Period V non-responders to olmesartan/amlodipine/hydrochlorothiazide 20mg/5mg/12.5 mg were up titrated to 40mg/5mg/12.5mg. A participant was considered a responder if their blood pressure was &lt;140/90 mm Hg; &lt;130/80 mm Hg if the participant had diabetes or chronic renal or cardiovascular disease.</description>
        </group>
        <group group_id="P13">
          <title>20/5/12.5mg Responder Continued on 20/5/12.5 mg</title>
          <description>In Period V non-responders to olmesartan/amlodipine/hydrochlorothiazide 20mg/5mg/12.5 mg continued on 20mg/5mg/12.5mg. A participant was considered a responder if their blood pressure was &lt;140/90 mm Hg; &lt;130/80 mm Hg if the participant had diabetes or chronic renal or cardiovascular disease.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>PeriodI-II (Randomized, Double-Blind)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="335"/>
                <participants group_id="P2" count="336"/>
                <participants group_id="P3" count="336"/>
                <participants group_id="P4" count="336"/>
                <participants group_id="P5" count="336"/>
                <participants group_id="P6" count="337"/>
                <participants group_id="P7" count="337"/>
                <participants group_id="P8" count="336"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
                <participants group_id="P2" count="325"/>
                <participants group_id="P3" count="323"/>
                <participants group_id="P4" count="309"/>
                <participants group_id="P5" count="315"/>
                <participants group_id="P6" count="322"/>
                <participants group_id="P7" count="319"/>
                <participants group_id="P8" count="311"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="25"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="17"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period III (Single-Blind)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2540">2543 completed Period 2. Three decided not to continue in the study=2540.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2520"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period IV (Double-Blind)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="228">2 did not continue in the study and 1837 responders went directly to Period VI. 228+453+2+1837=2520</participants>
                <participants group_id="P2" count="453"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="451"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period V (Double -Blind)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">677 completed Period 4. 1 did not continue and 2 erroneously responders were not counted = 674</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="135"/>
                <participants group_id="P10" count="119"/>
                <participants group_id="P11" count="194"/>
                <participants group_id="P12" count="151"/>
                <participants group_id="P13" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="134"/>
                <participants group_id="P10" count="119"/>
                <participants group_id="P11" count="193"/>
                <participants group_id="P12" count="151"/>
                <participants group_id="P13" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period VI (Open-Label)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1447">1837 from Period III+2 from Period IV + 670 from Period 5 = 2509</participants>
                <participants group_id="P2" count="272"/>
                <participants group_id="P3" count="480"/>
                <participants group_id="P4" count="146"/>
                <participants group_id="P5" count="164"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1408"/>
                <participants group_id="P2" count="264"/>
                <participants group_id="P3" count="467"/>
                <participants group_id="P4" count="143"/>
                <participants group_id="P5" count="157"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg</title>
        </group>
        <group group_id="B2">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg</title>
        </group>
        <group group_id="B3">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg</title>
        </group>
        <group group_id="B4">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg</title>
        </group>
        <group group_id="B5">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg</title>
        </group>
        <group group_id="B6">
          <title>Olmesartan/Amlodipine 20mg/5mg</title>
        </group>
        <group group_id="B7">
          <title>Olmesartan/Amlodipine 40mg/5mg</title>
        </group>
        <group group_id="B8">
          <title>Olmesartan/Amlodipine 40mg/10mg</title>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="335"/>
            <count group_id="B2" value="336"/>
            <count group_id="B3" value="336"/>
            <count group_id="B4" value="336"/>
            <count group_id="B5" value="336"/>
            <count group_id="B6" value="337"/>
            <count group_id="B7" value="337"/>
            <count group_id="B8" value="336"/>
            <count group_id="B9" value="2689"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" spread="10.81"/>
                    <measurement group_id="B2" value="56.8" spread="10.36"/>
                    <measurement group_id="B3" value="56.5" spread="10.92"/>
                    <measurement group_id="B4" value="57.0" spread="10.72"/>
                    <measurement group_id="B5" value="55.9" spread="11.08"/>
                    <measurement group_id="B6" value="56.1" spread="10.22"/>
                    <measurement group_id="B7" value="56.4" spread="10.4"/>
                    <measurement group_id="B8" value="57.0" spread="9.70"/>
                    <measurement group_id="B9" value="56.5" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="184"/>
                    <measurement group_id="B4" value="181"/>
                    <measurement group_id="B5" value="178"/>
                    <measurement group_id="B6" value="185"/>
                    <measurement group_id="B7" value="170"/>
                    <measurement group_id="B8" value="192"/>
                    <measurement group_id="B9" value="1443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="155"/>
                    <measurement group_id="B5" value="158"/>
                    <measurement group_id="B6" value="152"/>
                    <measurement group_id="B7" value="167"/>
                    <measurement group_id="B8" value="144"/>
                    <measurement group_id="B9" value="1246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="334"/>
                    <measurement group_id="B2" value="336"/>
                    <measurement group_id="B3" value="335"/>
                    <measurement group_id="B4" value="335"/>
                    <measurement group_id="B5" value="336"/>
                    <measurement group_id="B6" value="337"/>
                    <measurement group_id="B7" value="337"/>
                    <measurement group_id="B8" value="335"/>
                    <measurement group_id="B9" value="2685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="335"/>
                    <measurement group_id="B2" value="336"/>
                    <measurement group_id="B3" value="336"/>
                    <measurement group_id="B4" value="336"/>
                    <measurement group_id="B5" value="336"/>
                    <measurement group_id="B6" value="337"/>
                    <measurement group_id="B7" value="337"/>
                    <measurement group_id="B8" value="336"/>
                    <measurement group_id="B9" value="2689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Seated Diastolic Blood Pressure (SeDBP).</title>
        <description>Baseline blood pressure was defined as the average values obtained at the randomization visit and at the visit prior to randomization</description>
        <time_frame>Baseline to week 10</time_frame>
        <population>The full analysis set includes 2679 randomized patients who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period I-II</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 20 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet</description>
          </group>
          <group group_id="O2">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + 2 tablets of hydroclororthiazide 12.5 mg</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet</description>
          </group>
          <group group_id="O5">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + 2 tablets of hydroclororthiazide 12.5 mg</description>
          </group>
          <group group_id="O6">
            <title>Olmesartan/Amlodipine 20mg/5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 20 mg/amlodipine 5 mg + two 12.5 mg hydrochlorothiazide placebo tablets</description>
          </group>
          <group group_id="O7">
            <title>Olmesartan/Amlodipine 40mg/5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + two 12.5 mg hydrochlorothiazide placebo tablets</description>
          </group>
          <group group_id="O8">
            <title>Olmesartan/Amlodipine 40mg/10mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + two 12.5 mg hydrochlorothiazide placebo tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Seated Diastolic Blood Pressure (SeDBP).</title>
          <description>Baseline blood pressure was defined as the average values obtained at the randomization visit and at the visit prior to randomization</description>
          <population>The full analysis set includes 2679 randomized patients who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period I-II</population>
          <units>mm HG</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="336"/>
                <count group_id="O3" value="335"/>
                <count group_id="O4" value="336"/>
                <count group_id="O5" value="332"/>
                <count group_id="O6" value="337"/>
                <count group_id="O7" value="334"/>
                <count group_id="O8" value="335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.5" spread="0.48"/>
                    <measurement group_id="O2" value="-22.5" spread="0.48"/>
                    <measurement group_id="O3" value="-23.0" spread="0.48"/>
                    <measurement group_id="O4" value="-23.9" spread="0.47"/>
                    <measurement group_id="O5" value="-23.8" spread="0.48"/>
                    <measurement group_id="O6" value="-20.5" spread="0.47"/>
                    <measurement group_id="O7" value="-21.2" spread="0.48"/>
                    <measurement group_id="O8" value="-22.1" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0071</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0323</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0080</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0071</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0107</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Seated Systolic Blood Pressure (SeDBP).</title>
        <time_frame>Baseline to week 10</time_frame>
        <population>The full analysis set includes 2679 randomized patients who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period I-II</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 20 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet</description>
          </group>
          <group group_id="O2">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + 2 tablets of hydroclororthiazide 12.5 mg</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet</description>
          </group>
          <group group_id="O5">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + 2 tablets of hydroclororthiazide 12.5 mg</description>
          </group>
          <group group_id="O6">
            <title>Olmesartan/Amlodipine 20mg/5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 20 mg/amlodipine 5 mg + two 12.5 mg hydrochlorothiazide placebo tablets</description>
          </group>
          <group group_id="O7">
            <title>Olmesartan/Amlodipine 40mg/5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + two 12.5 mg hydrochlorothiazide placebo tablets</description>
          </group>
          <group group_id="O8">
            <title>Olmesartan/Amlodipine 40mg/10mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + two 12.5 mg hydrochlorothiazide placebo tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Seated Systolic Blood Pressure (SeDBP).</title>
          <population>The full analysis set includes 2679 randomized patients who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period I-II</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="336"/>
                <count group_id="O3" value="335"/>
                <count group_id="O4" value="336"/>
                <count group_id="O5" value="332"/>
                <count group_id="O6" value="337"/>
                <count group_id="O7" value="334"/>
                <count group_id="O8" value="335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.2" spread="0.72"/>
                    <measurement group_id="O2" value="-33.7" spread="0.72"/>
                    <measurement group_id="O3" value="-35.3" spread="0.71"/>
                    <measurement group_id="O4" value="-35.5" spread="0.71"/>
                    <measurement group_id="O5" value="-36.2" spread="0.72"/>
                    <measurement group_id="O6" value="-29.9" spread="0.71"/>
                    <measurement group_id="O7" value="-30.4" spread="0.71"/>
                    <measurement group_id="O8" value="-32.8" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reaching Blood Pressure Goal at Week 10</title>
        <description>Blood pressure treatment goal was defined as blood pressure &lt;140/90 mmHg or &lt;130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease.</description>
        <time_frame>baseline to week 10</time_frame>
        <population>The full analysis set includes 2679 randomized patients who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period I-II</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 20 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet</description>
          </group>
          <group group_id="O2">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + 2 tablets of hydroclororthiazide 12.5 mg</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet</description>
          </group>
          <group group_id="O5">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + 2 tablets of hydroclororthiazide 12.5 mg</description>
          </group>
          <group group_id="O6">
            <title>Olmesartan/Amlodipine 20mg/5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 20 mg/amlodipine 5 mg + two 12.5 mg hydrochlorothiazide placebo tablets</description>
          </group>
          <group group_id="O7">
            <title>Olmesartan/Amlodipine 40mg/5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + two 12.5 mg hydrochlorothiazide placebo tablets</description>
          </group>
          <group group_id="O8">
            <title>Olmesartan/Amlodipine 40mg/10mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + two 12.5 mg hydrochlorothiazide placebo tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reaching Blood Pressure Goal at Week 10</title>
          <description>Blood pressure treatment goal was defined as blood pressure &lt;140/90 mmHg or &lt;130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease.</description>
          <population>The full analysis set includes 2679 randomized patients who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period I-II</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="336"/>
                <count group_id="O3" value="335"/>
                <count group_id="O4" value="336"/>
                <count group_id="O5" value="332"/>
                <count group_id="O6" value="337"/>
                <count group_id="O7" value="334"/>
                <count group_id="O8" value="335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="176"/>
                    <measurement group_id="O3" value="197"/>
                    <measurement group_id="O4" value="190"/>
                    <measurement group_id="O5" value="179"/>
                    <measurement group_id="O6" value="144"/>
                    <measurement group_id="O7" value="155"/>
                    <measurement group_id="O8" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0295</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2529</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0037</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2033</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2529</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Seated Diastolic Blood Pressure From Week 18 to Week 22</title>
        <time_frame>Week 18 to week 22</time_frame>
        <population>The Full Analysis Set 2=681 randomized participants who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period IV</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 20 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg.
hydrochlorothiazide placebo tablet. Participants from Period III who did not meet blood pressure goals (&lt;140/90; 130/80 for participants with diabetes, chronic renal disease, or chronic cardiovascular disease)were randomized to Period IV in a 1:2 ratio to continue olm/aml/hctz 20/5/12.5 or be up-titrated to olm/aml/hctz 40/5/12.5.</description>
          </group>
          <group group_id="O2">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet.
Participants from Period III who did not meet blood pressure goals (&lt;140/90; 130/80 for participants with diabetes, chronic renal disease, or chronic cardiovascular disease)were randomized to Period IV in a 1:2 ratio to continue olm/aml/hctz 20/5/12.5 or be up-titrated to olm/aml/hctz 40/5/12.5.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Seated Diastolic Blood Pressure From Week 18 to Week 22</title>
          <population>The Full Analysis Set 2=681 randomized participants who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period IV</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="453"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="0.47"/>
                    <measurement group_id="O2" value="-4.1" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1135</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Seated Systolic Blood Pressure From Week 18 to Week 22</title>
        <time_frame>Week 18 to week 22</time_frame>
        <population>The Full Analysis Set 2=681 randomized participants who received at least 1 dose of double-blind medication and who provided at least one blood pressure measurement in Period IV</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 20 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg.
hydrochlorothiazide placebo tablet. Participants from Period III who did not meet blood pressure goals (&lt;140/90; 130/80 for participants with diabetes, chronic renal disease, or chronic cardiovascular disease)were randomized to Period IV in a 1:2 ratio to continue olm/aml/hctz 20/5/12.5 or be up-titrated to olm/aml/hctz 40/5/12.5.</description>
          </group>
          <group group_id="O2">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg.
hydrochlorothiazide placebo tablet. Participants from Period III who did not meet blood pressure goals (&lt;140/90; 130/80 for participants with diabetes, chronic renal disease, or chronic cardiovascular disease)were randomized to Period IV in a 1:2 ratio to continue olm/aml/hctz 20/5/12.5 or be up-titrated to olm/aml/hctz 40/5/12.5.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Seated Systolic Blood Pressure From Week 18 to Week 22</title>
          <population>The Full Analysis Set 2=681 randomized participants who received at least 1 dose of double-blind medication and who provided at least one blood pressure measurement in Period IV</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="453"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="0.71"/>
                    <measurement group_id="O2" value="-6.5" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2765</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reaching Blood Pressure Goal From Week 18 to Week 22</title>
        <description>Blood pressure treatment goal was defined as blood pressure &lt;140/90 mmHg or &lt;130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease.</description>
        <time_frame>Week 18 to week 22</time_frame>
        <population>The Full Analysis Set 2=681 randomized participants who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period IV</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 20 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg.
hydrochlorothiazide placebo tablet. Participants from Period III who did not meet blood pressure goals (&lt;140/90; 130/80 for participants with diabetes, chronic renal disease, or chronic cardiovascular disease)were randomized to Period IV in a 1:2 ratio to continue olm/aml/hctz 20/5/12.5 or be up-titrated to olm/aml/hctz 40/5/12.5.</description>
          </group>
          <group group_id="O2">
            <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg</title>
            <description>Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg.
hydrochlorothiazide placebo tablet. Participants from Period III who did not meet blood pressure goals (&lt;140/90; 130/80 for participants with diabetes, chronic renal disease, or chronic cardiovascular disease)were randomized to Period IV in a 1:2 ratio to continue olm/aml/hctz 20/5/12.5 or be up-titrated to olm/aml/hctz 40/5/12.5.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reaching Blood Pressure Goal From Week 18 to Week 22</title>
          <description>Blood pressure treatment goal was defined as blood pressure &lt;140/90 mmHg or &lt;130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease.</description>
          <population>The Full Analysis Set 2=681 randomized participants who received at least 1 dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period IV</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="453"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4964</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Seated Diastolic Blood Pressure From Week 22 to Week 26</title>
        <time_frame>Week 22 to week 26</time_frame>
        <population>The Full Analysis Set 3=312 randomized participants who received at least one dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period V.</population>
        <group_list>
          <group group_id="O1">
            <title>OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5</title>
            <description>This arm contain participants who did not responded to olmesartan\amlodipine\hydrochlorothiazide 40/5/12.5 and who were randomized to that combination in Period V</description>
          </group>
          <group group_id="O2">
            <title>OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25</title>
            <description>This arm contain participants who did not respond to olmesartan\amlodipine\hydrochlorothiazide 40/5/12.5 and who were randomized to 40/5/25 in Period V</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Seated Diastolic Blood Pressure From Week 22 to Week 26</title>
          <population>The Full Analysis Set 3=312 randomized participants who received at least one dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period V.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="0.68"/>
                    <measurement group_id="O2" value="-3.8" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1301</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01301</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Seated Systolic Blood Pressure From Week 22 to Week 26</title>
        <time_frame>Week 22 to week 26</time_frame>
        <population>The Full Analysis Set 3=312 randomized participants who received at least one dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period V.</population>
        <group_list>
          <group group_id="O1">
            <title>OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5</title>
            <description>This arm contain participants who did not responded to olmesartan\amlodipine\hydrochlorothiazide 40/5/12.5 and who were randomized to that combination in Period V</description>
          </group>
          <group group_id="O2">
            <title>OLM/AML/HCTZ40/5/12.5mg Nonresponders Randomized to 40/5/25</title>
            <description>This arm contain participants who did not respond to olmesartan\amlodipine\hydrochlorothiazide 40/5/12.5 and who were randomized to 40/5/25 in Period V</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Seated Systolic Blood Pressure From Week 22 to Week 26</title>
          <population>The Full Analysis Set 3=312 randomized participants who received at least one dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period V.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="1.01"/>
                    <measurement group_id="O2" value="-6.7" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0503</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reaching Blood Pressure Goal at Week 26</title>
        <description>Blood pressure treatment goal was defined as blood pressure &lt;140/90 mmHg or &lt;130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease.</description>
        <time_frame>Week 22 to week 26</time_frame>
        <population>The Full Analysis Set 3=312 randomized participants who received at least one dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period V</population>
        <group_list>
          <group group_id="O1">
            <title>OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5</title>
            <description>This arm contain participants who did not responded to olmesartan\amlodipine\hydrochlorothiazide 40/5/12.5 and who were randomized to that combination in Period V</description>
          </group>
          <group group_id="O2">
            <title>OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25</title>
            <description>This arm contain participants who did not respond to olmesartan\amlodipine\hydrochlorothiazide 40/5/12.5 and who were randomized to 40/5/25 in Period V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reaching Blood Pressure Goal at Week 26</title>
          <description>Blood pressure treatment goal was defined as blood pressure &lt;140/90 mmHg or &lt;130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease.</description>
          <population>The Full Analysis Set 3=312 randomized participants who received at least one dose of double-blind medication and who provided at least one diastolic blood pressure measurement in Period V</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Seated Systolic Blood Pressure (SeDBP) During Open-Label Period VI (Titration Effect From OM/AML/HCTZ 40/5/25 to 40/10/25.</title>
        <time_frame>Week 26 to week 54</time_frame>
        <population>The number of subjects up titrated who had blood pressure values at both time points.</population>
        <group_list>
          <group group_id="O1">
            <title>OLM/AML/HCTZ 40/5/25 Titrated to 40/10/25</title>
            <description>The participants in this arm had their study medication titrated from olmesartan\amlodipine\hydrochlorothiazide 40/5/25 to 40/10/25</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Seated Systolic Blood Pressure (SeDBP) During Open-Label Period VI (Titration Effect From OM/AML/HCTZ 40/5/25 to 40/10/25.</title>
          <population>The number of subjects up titrated who had blood pressure values at both time points.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 1 to week 54</time_frame>
      <desc>All adverse events, whether observed by the investigator or reported by the participant were recorded on the Adverse Event electronic Case Report Form. Adverse events (AEs)were collected up to 14 days after the last study dose; for serious AEs considered to be drug related there was no time limit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg</title>
        </group>
        <group group_id="E2">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg</title>
        </group>
        <group group_id="E3">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg</title>
        </group>
        <group group_id="E4">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg</title>
        </group>
        <group group_id="E5">
          <title>Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg</title>
        </group>
        <group group_id="E6">
          <title>Olmesartan/Amlodipine 20mg/5mg</title>
        </group>
        <group group_id="E7">
          <title>Olmesartan/Amlodipine 40mg/5mg</title>
        </group>
        <group group_id="E8">
          <title>Olmesartan/Amlodipine 40mg/10mg</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Gastric Polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Mouth cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Peritonsillar abcess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Barotrauma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Vertebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Femeral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QRS complex shortened</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hepatitus B virus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Malignant fibrous histiocytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Removal of internal fixation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="38" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="30" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="30" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="334"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="332"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="333"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A site may not publish results until after a coordinated multicentre publication has been submitted for publication or until one year after the study has ended, whichever occurs first. Then, the site will have the opportunity to publish the results, provided that DSE has had the opportunity to review and comment on the site’s proposed publication prior to its being submitted for publication with the advice of company patent council and in accord with needs for subject protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bettina Ammentorp</name_or_title>
      <organization>Daiichi Sankyo Europe, GmbH</organization>
      <phone>00498978080</phone>
      <email>bettina.ammentorp@daiichi-sankyo.eu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

